Drug pipelines improving after years in doldrums

<p>LONDON (Reuters) Drug attention capability is finally improving after years of investigate disappointment, as drugmakers change their concentration from mass markets to creation medicines for rarer, under-treated diseases.
Data from Thomson Reuters published on Tuesday showed some-more new drugs are reaching a marketplace and that a attention has been enjoying aloft success rates in a dear final theatre of clinical development.
The series of innovative medicines, or new molecular entities, launched globally in 2011 strike a 10-year high of 31, adult from 21 in 2010.
Last years entrants enclosed poignant advances, such as new treatments from Roche and Bristol-Myers Squibb for melanoma, a initial new drug for lupus in half a century from GlaxoSmithKline, and dual new hepatitis C drugs from Merck and Vertex Pharmaceuticals.
The opinion is also improving for a subsequent call of products, with a series of experimental drugs ...